Home   >  

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products

Antibodies

Peptides

Catalysts

Impurities

Intermediate

Raw Materials

PI3K/Akt/mTOR

Chemical Structure Cat. No. Product Name CAS No.
BAY-1895344 hydrochloride Chemical Structure
BCP31861 BAY-1895344 hydrochloride BAY-1895344HCl
BAY-1895344 hydrochloride is a potent, orally available and selective ATR inhibitor, with IC50 of 7 nM. Anti-tumor activity.
Miransertib HCl Chemical Structure
BCP25709 Miransertib HCl 1313883-00-9
Miransertib (ARQ-092) is an orally bioavailable, selective, and potent allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively.
GNF4877 Chemical Structure
BCP31624 GNF4877 2041073-22-5
GNF4877 is a potent DYRK1A and GSK3β inhibitor with IC50s of 6 nM and 16 nM.
Ipatasertib dihydrochloride Chemical Structure
BCP23821 Ipatasertib dihydrochloride 1396257-94-5
Ipatasertib dihydrochloride is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5/18/8 nM, 620-fold selectivity over PKA.
Recilisib Chemical Structure
BCP31296 Recilisib 334969-03-8
Recilisib is a radioprotectant, which can activate AKT, PI3K activities in cells.
Pterosin B Chemical Structure
BCP09994 Pterosin B 34175-96-7
Pterosin B is isolated and purified from the aerial parts of Pteris semipinnata.
VP3.15 dihydrobromide Chemical Structure
BCP31222 VP3.15 dihydrobromide 1281681-33-1
VP3.15 dihydrobromide is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC50s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively.
VP3.15 Chemical Structure
BCP31223 VP3.15 1281681-54-6
VP3.15 is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC50s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively.
SL 0101-1 Chemical Structure
BCP21457 SL 0101-1 77307-50-7
SL0101 is a highly specific RSK inhibitor. SL0101 showed improved in vitro biological stability while maintaining specificity for RSK. These results should facilitate the development of RSK inhibitors derived from SL0101 as anticancer agents.
NVP-QAV-572 Chemical Structure
BCP27906 NVP-QAV-572 957209-68-6
NVP-QAV-572 is a potent PI3K kianse inhibitor.
123下一页末页共 301 条记录 1 / 31 页 
0086-15971444841